CeriBell, Inc. (NASDAQ:CBLL - Get Free Report)'s share price was down 6.1% during mid-day trading on Monday . The company traded as low as $17.81 and last traded at $17.77. Approximately 88,003 shares changed hands during trading, a decline of 70% from the average daily volume of 290,815 shares. The stock had previously closed at $18.93.
Analysts Set New Price Targets
Several equities analysts have commented on CBLL shares. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 price target for the company. BTIG Research began coverage on CeriBell in a report on Tuesday, June 24th. They issued a "buy" rating and a $30.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, CeriBell has a consensus rating of "Buy" and a consensus price target of $32.14.
View Our Latest Research Report on CBLL
CeriBell Trading Down 1.0%
The firm has a 50-day moving average price of $17.49 and a two-hundred day moving average price of $19.88. The company has a debt-to-equity ratio of 0.11, a quick ratio of 16.81 and a current ratio of 17.36.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The business had revenue of $20.49 million during the quarter, compared to analyst estimates of $19.30 million. Equities analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current year.
Insiders Place Their Bets
In other news, CEO Xingjuan Chao sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.00, for a total value of $425,000.00. Following the transaction, the chief executive officer owned 776,022 shares of the company's stock, valued at approximately $13,192,374. The trade was a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Rebecca B. Robertson sold 20,000 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $17.14, for a total value of $342,800.00. Following the completion of the transaction, the director directly owned 28,675 shares in the company, valued at approximately $491,489.50. The trade was a 41.09% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 113,333 shares of company stock worth $1,895,195. 20.10% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On CeriBell
Several institutional investors have recently bought and sold shares of CBLL. FMR LLC acquired a new position in CeriBell in the 4th quarter valued at $128,120,000. TPG GP A LLC acquired a new position in shares of CeriBell during the fourth quarter worth about $102,677,000. Red Tree Management LLC acquired a new position in shares of CeriBell during the fourth quarter worth about $57,083,000. Yu Fan acquired a new position in CeriBell during the 4th quarter worth approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd acquired a new position in CeriBell during the 4th quarter worth approximately $28,160,000.
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
See Also
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.